Post-RNA (mRNA) Vaccination Myocarditis: CMR Features

Karuna M. Das, Taleb Al Mansoori, Ali Al Shamisi, Usama M.H. Al Bastaki, Klaus V. Gorkom, Jamal Aldeen Al Koteesh

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


RNA (mRNA) vaccines used to prevent COVID-19 infection may cause myocarditis. We describe a case of acute myocarditis in a 27-year-old male after receiving the second dose of a Pfizer immunization. Three days after receiving the second dose of vaccine, he had acute chest pain. Elec-trocardiographic examination revealed non-specific ST-T changes in the inferior leads. Troponin levels in his laboratory tests were 733 ng/L. No abnormalities were detected on his echocardiog-raphy or coronary angiography. The basal inferoseptal segment was hypokinetic. The LV EF was 50%, whereas the RV EF was 46%. Epicardial and mesocardial LGE were shown in the left ven-tricle’s basal and mid anterolateral, posterolateral, and inferoseptal segments. The native T1 was 1265 ± 54 ms, and the native T2 was 57 ± 10 ms. Myocardial strain indicated that the baseline values for LV GLS (−14.55), RV GLS (−15.8), and RVCS (−6.88) were considerably lower. The diagnosis of acute myocarditis was determined based on the clinical presentation and cardiac magnetic resonance (CMR) findings.

Original languageEnglish
Article number1034
Issue number5
Publication statusPublished - May 2022


  • CMR
  • RNA (mRNA) vaccine
  • myocarditis

ASJC Scopus subject areas

  • Clinical Biochemistry


Dive into the research topics of 'Post-RNA (mRNA) Vaccination Myocarditis: CMR Features'. Together they form a unique fingerprint.

Cite this